Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc has reinforced its clinical and financial position through the successful completion of an $8M financing, which enables the advancement of its EB103 therapy into the Phase II segment of its ongoing Phase I/II study. The independent Data and Safety Monitoring Board's recommendation to proceed with the STARLIGHT-1 trial at the Recommended Phase II Dose marks a significant milestone, suggesting enhanced operational momentum as the company expands its patient cohorts and gathers additional safety and efficacy data. Furthermore, the innovative Artemis Technology platform, which aims to revolutionize CAR-T therapy, positions Estrella to capitalize on new market opportunities in treating both B-cell malignancies and solid tumors, supporting a positive outlook for the company's future growth.

Bears say

Estrella Immunopharma's outlook appears negative due to concerns over potential future dilution as indicated by the recent stock decline. Management's focus on discussing broader strategic priorities at the upcoming annual shareholders meeting implies uncertainty around critical developments in their pipeline and partnerships. Additionally, a conservative adjustment of assumptions has led to a significant reduction in their target price, reflecting a cautious approach to the company’s financial health and growth prospects.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Apr 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.